{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-005024","form_type":"8-K","ticker":"ELTP","cik":"0001053369","company_name":"ELITE PHARMACEUTICALS INC /NV/","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:43.679926+00:00","generated_at":"2026-06-19T12:59:20.165077+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Elite Pharma Q3 revenue $9.3M (+3% YoY), net income $2.96M","bullets":["Q3 FY2023 revenue $9.3M, up 3% from prior year; operating profit $2.0M.","Net income for Q3 was $2.96M; nine-month net income $4.79M.","Nine-month revenue $25.5M (+4% YoY); operating profit $4.1M (down $0.1M).","Growth driven by generic immediate-release and extended-release Adderall.","Conference call set for Feb 15, 2023 at 11:30 AM EST to discuss results."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-005024","json":"https://secwatch.observer/filing/0001493152-23-005024.json","markdown":"https://secwatch.observer/filing/0001493152-23-005024.md","text":"https://secwatch.observer/filing/0001493152-23-005024.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T12:59:20.165077+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c87157ed577eabc1ec8339c258828ad6c444c19","claim":"ELITE PHARMACEUTICALS INC /NV/ reported the nine-month period ended December 31, 2022 results: revenue $25.5 million, net income $4.79 million.","evidence_excerpt":"Consolidated revenues for the nine-month period ended December 31, 2022, were $25.5 million, an increase of $0.90 million or 4% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $4.1 million, a decrease of $0.10 million from the comparable period of the prior year, and net income was $4.79 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the nine-month period ended December 31, 2022"},{"label":"Revenue","value":"$25.5 million"},{"label":"Net income","value":"$4.79 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"b10790e80a4c06d377b1eb712180973052b9cd01","claim":"ELITE PHARMACEUTICALS INC /NV/ reported the third quarter of fiscal year 2023 ended December 31, 2022 results: revenue $9.3 million, net income $2.96 million.","evidence_excerpt":"Consolidated revenues for the three-month period ended December 31, 2022, were $9.3 million, an increase of $0.30 million or 3% as compared to the comparable period of the prior fiscal year. The increase was primarily attributed to revenues from generic immediate-release Adderall ® and generic extended-release Adderall ® . Operating profits were $2.0 million, an increase of $0.12 million from the prior year’s comparable period, and net income was $2.96 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1053369/000149315223005024/0001493152-23-005024-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of fiscal year 2023 ended December 31, 2022"},{"label":"Revenue","value":"$9.3 million"},{"label":"Net income","value":"$2.96 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}